行情

PTCT

PTCT

PTC Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

47.16
-0.84
-1.75%
交易中 14:58 08/12 EDT
开盘
48.32
昨收
48.00
最高
48.87
最低
46.99
成交量
69.25万
成交额
--
52周最高
59.89
52周最低
30.79
市值
31.93亿
市盈率(TTM)
-6.8296
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PTCT价格均价为60.22,最高价位86.00,最低价为46.00。

EPS

PTCT 新闻

更多
Credit Suisse Maintains Neutral on PTC Therapeutics, Lowers Price Target to $52
Credit Suisse maintains PTC Therapeutics (NASDAQ:PTCT) with a Neutral and lowers the price target from $53 to $52.
Benzinga · 2天前
PTC Therapeutics Scores Early FDA Nod For Evrysdi; Analyst Stays Sidelined
PTC Therapeutics (PTCT) has announced that the US Food and Drug Administration (FDA) has approved Evrysdi (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in adults and children 2 months and older. The treatment w
SmarterAnalyst · 2天前
Biogen's Alzheimer's Drug And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 3天前
FDA approves Roche's new spinal muscular atrophy drug
Roche Holding AG said Friday that the Food and Drug Administration had approved Evrysdi, a treatment for spinal muscular atrophy in adults and most children. It's the second drug to be approved by the regulator to treat the rare disease. The therapy was devel
MarketWatch · 4天前
PTC Therapeutics Looks Like A Better Value After Recent Pullback
Seeking Alpha - Article · 4天前
FDA OKs PTC Therapeutics' spinal muscular atrophy treatment Evrysdi
Seeking Alpha - Article · 5天前
PTC Therapeutics Announces FDA Approval of Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in adults and children 2 months and old
PR Newswire · 5天前
PTC Therapeutics' Mary Frances Harmon Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine
PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its Senior Vice President of Corporate and Patient Relations, Mary Frances Harmon, has been named to PharmaVOICE magazine's annual list of the most inspiring people in the life sciences industry.
PR Newswire · 6天前

所属板块

生物技术和医学研究
+0.45%
制药与医学研究
+1.64%

热门股票

代码
价格
涨跌幅

PTCT 简况

PTC Therapeutics, Inc.是一家致力于发现、开发和商业化针对转录后调控过程的口服小分子疗法的生物制药公司。该公司的主导产品Translarna(ataluren)治疗5岁及以上非卧床患者的无义突变杜兴氏肌肉营养不良症(nmDMD)。该公司的项目包括治疗无义突变囊肿性纤维化(nmCF)、无义突变引起的粘多糖贮积证I型(nmMPS I)、无义突变虹膜缺损、无义突变Dravet综合征/CDKL5的多个Translarna项目,与Spinal Muscular Atrophy Foundation(SMA Foundation)和F.Hoffman-La Roche Ltd及Hoffman-La Roche Inc.(统称为Roche)合作的脊髓性肌肉萎缩证(SMA)研究项目,以及癌症干细胞项目(PTC596)。该公司在SMA项目中拥有处于临床开发阶段的两种化合物:RG7800和RG7916。
展开

微牛提供PTC Therapeutics, Inc.(NASDAQ-PTCT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PTCT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PTCT股票基本功能。